BIOCYTOGEN-B Surges Over 6% in Early Trading as RenBiologics Unit Enters Commercialization Phase

Stock News05-20

BIOCYTOGEN-B (02315) rose more than 6% in early trading. As of press time, the stock was up 6.03% to HK$50.85, with a turnover of HK$42.8952 million. The company recently participated in the AACR Annual Meeting, where it showcased 36 latest research findings in poster presentations. These covered various drug modalities including fully human monoclonal antibodies, bispecific/multispecific antibodies, antibody-drug conjugates (ADCs) and bispecific antibody-drug conjugates, nanobodies, and TCR molecules, along with 12 preclinical animal model and pharmacodynamic research updates. This comprehensive display highlighted the latest progress and synergistic advantages of its "Thousand Mice Ten Thousand Antibodies" and "BioMice" platforms. A research report from China Securities stated that the company's BioMice business is benefiting from growing demand for target-humanized mice, expansion of multinational corporation (MNC) clients, and enhanced overseas service capabilities, with revenue expected to maintain rapid growth. The RenBiologics business has entered a commercialization realization phase, where antibody molecule transfers, platform licensing, milestone payments, and potential sales royalties are anticipated to form long-term growth drivers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118832957?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118832957","market":"sh","top_or_hot":-1,"title":"BIOCYTOGEN-B Surges Over 6% in Early Trading as RenBiologics Unit Enters Commercialization Phase","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) rose more than 6% in early trading. As of press time, the stock was up 6.03% to HK$50.85, with a turnover of HK$42.8952 million.\nThe company recently participated in the AACR Annual Meeting, where it showcased 36 latest research findings in poster presentations. These covered various drug modalities including fully human monoclonal antibodies, bispecific/multispecific antibodies, antibody-drug conjugates (ADCs) and bispecific antibody-drug conjugates, nanobodies, and TCR molecules, along with 12 preclinical animal model and pharmacodynamic research updates. This comprehensive display highlighted the latest progress and synergistic advantages of its \"Thousand Mice Ten Thousand Antibodies\" and \"BioMice\" platforms.\nA research report from China Securities stated that the company's BioMice business is benefiting from growing demand for target-humanized mice, expansion of multinational corporation (MNC) clients, and enhanced overseas service capabilities, with revenue expected to maintain rapid growth. The RenBiologics business has entered a commercialization realization phase, where antibody molecule transfers, platform licensing, milestone payments, and potential sales royalties are anticipated to form long-term growth drivers.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B Surges Over 6% in Early Trading as RenBiologics Unit Enters Commercialization Phase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B Surges Over 6% in Early Trading as RenBiologics Unit Enters Commercialization Phase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-20 11:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) rose more than 6% in early trading. As of press time, the stock was up 6.03% to HK$50.85, with a turnover of HK$42.8952 million.\nThe company recently participated in the AACR Annual Meeting, where it showcased 36 latest research findings in poster presentations. These covered various drug modalities including fully human monoclonal antibodies, bispecific/multispecific antibodies, antibody-drug conjugates (ADCs) and bispecific antibody-drug conjugates, nanobodies, and TCR molecules, along with 12 preclinical animal model and pharmacodynamic research updates. This comprehensive display highlighted the latest progress and synergistic advantages of its \"Thousand Mice Ten Thousand Antibodies\" and \"BioMice\" platforms.\nA research report from China Securities stated that the company's BioMice business is benefiting from growing demand for target-humanized mice, expansion of multinational corporation (MNC) clients, and enhanced overseas service capabilities, with revenue expected to maintain rapid growth. The RenBiologics business has entered a commercialization realization phase, where antibody molecule transfers, platform licensing, milestone payments, and potential sales royalties are anticipated to form long-term growth drivers.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1118832957","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118832957","pubTimestamp":1779246880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) rose more than 6% in early trading. As of press time, the stock was up 6.03% to HK$50.85, with a turnover of HK$42.8952 million. The company recently participated in the AACR...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK0216":"研究试验","02315":"百奥赛图-B","BK1161":"生物科技","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念"},"translate_title":"随着RenBiologics部门进入商业化阶段，百奥赛图-B早盘飙升逾6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"02315":1,"VXUS":1},"content_text":"BIOCYTOGEN-B (02315) rose more than 6% in early trading. As of press time, the stock was up 6.03% to HK$50.85, with a turnover of HK$42.8952 million.\nThe company recently participated in the AACR Annual Meeting, where it showcased 36 latest research findings in poster presentations. These covered various drug modalities including fully human monoclonal antibodies, bispecific/multispecific antibodies, antibody-drug conjugates (ADCs) and bispecific antibody-drug conjugates, nanobodies, and TCR molecules, along with 12 preclinical animal model and pharmacodynamic research updates. This comprehensive display highlighted the latest progress and synergistic advantages of its \"Thousand Mice Ten Thousand Antibodies\" and \"BioMice\" platforms.\nA research report from China Securities stated that the company's BioMice business is benefiting from growing demand for target-humanized mice, expansion of multinational corporation (MNC) clients, and enhanced overseas service capabilities, with revenue expected to maintain rapid growth. The RenBiologics business has entered a commercialization realization phase, where antibody molecule transfers, platform licensing, milestone payments, and potential sales royalties are anticipated to form long-term growth drivers.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118832957","isCrawlerRequest":true}